Variability in human hepatic MRP4 expression: Influence of cholestasis and genotype

Pharmacogenomics Journal

Volumn 8, Issue 1, 2008, Pages 42-52

  Gradhand, U ^a   Lang, T ^b   Schaeffeler, E ^c,d   Glaeser, H ^a   Tegude, H ^c,d   Klein, K ^c,d   Fritz, P ^e   Jedlitschky, G ^f   Kroemer, H K ^f   Bachmakov, I ^a   Anwald, B ^g   Kerb, R ^g   Zanger, U M ^c,d   Eichelbaum, M ^c,d   Schwab, M ^c,d,h   Fromm, M F ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e ROBERT BOSCH HOSPITAL   (Germany)

^f UNIVERSITY OF GREIFSWALD   (Germany)

^g Epidauros Biotechnologie AG   (Germany)

^h UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 4; XENOBIOTIC AGENT;

ARTICLE; CELLULAR DISTRIBUTION; CHOLESTASIS; CONTROLLED STUDY; DNA FLANKING REGION; DNA SEQUENCE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UPREGULATION;

ADULT; CHOLESTASIS; DNA; FEMALE; GENE EXPRESSION REGULATION; GENOTYPE; HAPLOTYPES; HUMANS; IMMUNOHISTOCHEMISTRY; INTRONS; LIVER; MALE; MICROSCOPY, FLUORESCENCE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN CONFORMATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TERMINOLOGY AS TOPIC; VARIATION (GENETICS);

EID: 38349090221     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500451     Document Type: Article

References (39)

1. Ho RH, Kim RB. Transporters and drug therapy: Implications for drug disposition and disease. Clin Pharmacol Ther 2005; 78: 260-277.
2. Ito K, Suzuki H, Horie T, Sugiyama Y. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm Res 2005; 22: 1559-1577.
3. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 2004; 25: 423-429.
4. Keppler D. Uptake and efflux transporters for conjugates in human hepatocytes. Methods Enzymol 2005; 400: 531-542.
5. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 2006; 112: 457-473.
6. Borst P, de Wolf C, van de Wetering K. Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch 2007; 453: 661-673.
7. Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, Keppler D. Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 2003; 38: 374-384.
8. van Aubel RA, Smeets PH, Peters JG, Bindels RJ, Russel FG. The MRP4/ ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: Putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 2002; 13: 595-603.
9. Wielinga PR, van der Heijden I, Reid G, Beijnen JH, Wijnholds J, Borst P. Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells. J Biol Chem 2003; 278: 17664-17671.
10. Zelcer N, Reid G, Wielinga P, Kuil A, van der Heijden I, Schuetz JD et al. Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J 2003; 371: 361-367.
11. Rius M, Hummel-Eisenbeiss J, Hofmann AF, Keppler D. Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione. Am J Physiol Gastrointest Liver Physiol 2006; 290: G640-649.
12. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kull A, de Haas M et al. The human multidrug resistince protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal anti-inflammatory drugs. Proc Natl Acad Sci USA 2003; 100: 9244-9249.
13. Zamek-Gliszczynski MJ, Nezasa KJ, Tian X, Bridges AS, Lee K, Belinsky MG et al. Evaluation of the role of multidrug resistance-associated protein (Mrp) 3 and Mrp4 in hepatic basolateral excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in Abcc3-/- and Abcc4-/- mice. J Pharmacol Exp Ther 2006; 319: 1485-1491.
14. Sampath J, Adachi M, Hatse S, Naesens L, Balzarini J, Flatley RM et al. Role of MRP4 and MRP5 in biology and chemotherapy. AAPS Pharm Sci 2002; 4: E14.
15. Assem M, Schuetz EG, Leggas M, Sun D, Yasuda K, Reid G et al. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J Biol Chem 2004, 279: 22250-22257.
16. Wagner M, Halilbasic E, Marschall HU, Zollner G, Fickert P, Langner C et al. CAR and PXR agohists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology 2005; 42: 420-430.
17. Schuetz EG, Strom S, Yasuda K, Lecureur V, Assem M, Brimer C et al Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem 2001; 276: 39411-39418.
18. Denk GU, Soroka CJ, Takeyama Y, Chen WS, Schuetz JD, Boyer JL. Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat. J Hepatol 2004; 40: 585-591.
19. Mennone A, Soroka CJ, Cai SY, Harry K, Adachi M, Hagey L et al. Mrp4-/- mice have an impaired cytoprotective response in obstructive cholestasis. Hepatology 2006; 43: 1013-1021.
20. Keitel V, Burdelski M, Warskulat U, Kuhlkamp T, Keppler D, Haussinger D et al. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology 2005; 41: 1160-1172.
21. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV et al. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 1999; 5: 1048-1051.
22. Borst P, Balzarini J, Ono N, Reid G, de Vries H, Wielinga P et al. The potential impact of drug transporters on nucleoside-analog-based antiviral chemotherapy. Antiviral Res 2004; 62: 1-7.
23. Adachi M, Sampath J, Lan LB, Sun D, Hargrove P, Flatley R et al. Expression of MRP4 confers resistance to ganciclovir and compromises bystander cell killing. J Biol Chem 2002; 277: 38998-39004.
24. Wielinga PR, Reid G, Challa EE, van der Heijden I, van Deemter L, de Haas M et al. Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Mol Pharmacol 2002; 62: 1321-1331.
25. Chen ZS, Lee K, Kruh GD. Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem 2001; 276: 33747-33754.
26. Anderson PL, Lamba J, Aquilante CL, Schuetz E, Fletcher CV. Pharmacogenetic Characteristics of Indinavir, Zidovudine, and Lamivudine Therapy in HIV-Infected Adults: A Pilot Study. J Acquir Immune Defic Syndr 2006; 42: 441-449.
27. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68 978-989.
28. Marschall HU, Wagner M, Zollner G, Fickert P, Diczfalusy U, Gumhold J et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 2005; 129: 476-485.
29. Stedman C, Liddle C, Coulter S, Sonoda J, Alvarez JG, Evans RM et al Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proc Natl Acad Sci USA 2006; 103: 11321-11328.
30. Wagner M, Fickert P, Zollner G, Fuchsbichler A, Silbert D, Tsybrovskyy O et al. Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology 2003; 125: 825-838.
31. Boyer JL, Trauner M, Mennone A, Soroka CJ, Cai S-Y, Moustafa T et al Upregulation of a basolateral FXR-dependent bile acid efflux transporter OST(alpha)-OSTbeta in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver Physiol 2006, 290: G1124-G1130.
32. Maher JM, Cheng X, Tanaka Y, Scheffer GL, Klaassen CD. Hormonal regulation of renal multidrug resistance-associated proteins 3 and 4 (Mrp3 and Mrp4) in mice. Biochem Pharmacol 2006; 72: 512-522.
33. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U et al Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001; 11: 399-415.
34. Hitzl W, Klein K, Zanger UM, Fritz P, Nussler AK, Neuhaus P et al. Influence of omeprazole on multidrug resistance protein 3 expression in human liver. J Pharmacol Exp Ther 2003; 304: 524-530.
35. den Dunnen JT, Antonarakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations: A discussion. Hum Mutat 2000; 15: 7-12.
36. König J, Cui Y, Nies AT, Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 2000; 278: G156-164.
37. Jedlitschky G, Tirschmann K, Lubenow LE, Nieuwenhuis HK, Akkerman JW, Greinacher A et al. The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage. Blood 2004; 104: 3603-3610.
38. Pschyrembel W. Pschyrembel: Klinisches Wörterbuch/Pschyrembel Clinical Dictionary. 259th German edition, de Gruyter: Berlin, New York, 2002.
39. Saito S, Iida A, Sekine A, Miura Y, Ogawa C, Kawauchi S et al. Identification of 779 genetic variations in eight genes encoding members of the ATP-binding cassette, subfamily C (ABCC/MRP/CFTR). J Hum Genet 2002; 47: 147-171.